Keywords
Epilepsia
Epilepsia Resistente a Medimento.
How to Cite
Abstract
This article aims to conduct a literature survey and analyze the importance and efficacy of the therapeutic use of Cannabidiol (CBD) in the treatment of epilepsy, as well as explore its benefits. This is an integrative review research, and the following indexes were used for the searches: Virtual Health Library (BVS), Latin American and Caribbean Database of Health Sciences Information (LILACS), National Library of Medicine (PUBMED) and the Online Medical Literature Search and Analysis System (MedLine) through the terms contained in the structured vocabulary of Health Sciences Descriptors (DeCS). Severe epilepsies are characterized by frequent seizures and in the vast majority of cases conventional treatment does not have the desired effect, causing a major impact on the quality of life of those living with this condition. Thus, studies show that an effective alternative would be CBD-based treatment, which acts by significantly reducing the frequency of epileptic seizures, especially epilepsies resistant to conventional treatment, Lennox-Gastaut Syndrome, Dravet Syndrome, Doose Syndrome, Idiopathic Epilepsy and Refractory Developmental Epileptic Encephalopathies among children, adolescents and adults. It is concluded that although the use of cannabis, especially cannabidiol (CBD), has proven to be effective and safe in the treatment of epilepsy, acting to reduce the frequency of epileptic seizures, there are still limitations in current knowledge and regulatory issues that restrict its specific and expanded use.
Keywords: Cannabidiol; Epilepsy; and Drug-Resistant Epilepsy.
References
Brasil. Minitério da Saúde. Secretária de Atenção a Saúde. Portaria Conjunta nº 17, de 21 de junho de 2018. Brasilia, 2018.
Dahmer DSV, Ferreira FPS, Bonfanti JW, Camargo EB; Elias FTS. O uso do canabidiol em crianças com epilepsia resistente a medicamento e a diminuição na frequência das crises: revisão rápida. Rev. Cient. Esc. Estadual Saúde Pública Goiás Cândido Santiago. 2023; 9(9f1-EE3):1-17.
Pereira, F. A. et al. (2018) Efeitos do canabidiol na frequência das crises epilépticas. Revista Brasileira de Neurologia e Psiquiatria. 2018; 1(22): 86-100.
Brasil. Minitério da Saúde. Canabidiol 200mg/ml para o tratamento de crianças e adolescentes com epilepsia refratária a medicamentos antiepilépticos. Relatório de Recomendação – Medicamento. Brasilia, 2021.
Carvalho CR, Hoeller AA, Franco PLC, Eidt I, Walz R. Canabinoides e Epilepsia: potencial terapêutico do canabidiol. Vittalle Revista de Ciências da Saúde. 2017; 1(9): 54-63.
Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2012 Jun 13; (6):CD009270. doi: 10.1002/14651858.CD009270.pub2. Update in: Cochrane Database Syst Rev. 2014 Mar 05;(3):CD009270. doi: 10.1002/14651858.CD009270.pub3. PMID: 22696383.
García-Peñas JJ, Gil Nagel-Rein A, Sánchez-Carpintero R, Villanueva-Haba V. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain. Rev Neurol. 2021 Sep 10; 73(S01):S1-S8. English, Spanish. doi: 10.33588/rn.73S01.2021250. PMID: 34486101.
Teles ABGPP, Souza BC, Oliveira ES, Araújo JN, Filho JWA, Alves V L OF, et al. O uso do canabidiol no tratamento da epilepsia: uma revisão sistemática. 2024; 28(129). DOI: 10.69849/revistaft/ni10202410131448
Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Canabinóides vegetais não psicotrópicos: novas oportunidades terapêuticas de uma erva antiga. Trends Pharmacol Sci. 2009 outubro; 30(10):515-27. DOI: 10.1016/j.tips.2009.07.006. Epub 2009 2 de setembro. Errata em: Trends Pharmacol Sci. 2009 Dez; 30(12):609. PMID: 19729208.
Souza MT de, Silva MD da, Carvalho R de. Revisão integrativa: o que é e como fazer. Einstein. 2010; 8(1):102-6. https://doi.org/10.1590/s1679- 45082010rw1134
Porter BE, Jacobson C. Relatório de uma pesquisa com pais sobre o uso de cannabis enriquecida com canabidiol na epilepsia resistente ao tratamento pediátrico. Comportamento da epilepsia. 2013; 29(3):574-7. DOI: 10.1016/j.yebeh.2013.08.037. PMID: 24237632; PMCID: PMC4157067.
Gunning B, Mazurkiewicz Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure. 2016;35:41-4. doi: 10.1016/j.seizure.2016.01.004. Epub 2016 Jan 6. PMID: 26800377.
Gunning B, Mazurkiewicz-Bełdzińska M, Chin RFM, Bhathal H, Nortvedt C, Dunayevich E, Checketts D. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurol Scand. 2021;143(2):154-163. doi: 10.1111/ane.13351. Epub 2020 Oct 22. PMID: 32969022; PMCID: PMC7821324.
Caraballo R, Reyes V G, Dermijian G. Use of medicinal cannabis in children with drug-resistant epileptic encephalopathies. Experience at Garrahan Hospital. Revista Medicina Infantil. 2022; 29(3): 205-211.
Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, et al. CBD EAP study group. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019;154:13-20. doi: 10.1016/j.eplepsyres.2019.03.015. Epub 2019 Mar 25. PMID: 31022635.
Portela R, Mota DM, Ferreira PJG, Lula MD, Reis BB, Oliveira HN, Ruas CM. Judicialização de produtos à base de canabidiol no Brasil: uma análise de 2019 a 2022. Caderno de Saúde Pública. 2023; 39(8):e00024723. doi: 10.1590/0102-311XPT024723.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 JOENA GABRIELA SILVA MORAIS, TÂMIA RAYARA CARVALHO ARAÚJO DA SILVA, POLLYANNA NASCIMENTO DA SILVA, DANILO PEREIRA PINHEIRO, ESTHER LOBATO BRITO, EMILLY LUISE MOURA DE SOUSA, BLENDA SILVA DOS SANTOS, EMANUELY PEREIRA ANTERO, LUANA REIS CARNEIRO, JOSÉ RICARDO PATRÍCIO DA SILVA SOUZA